To appreciate why the in vivo approach has generated such intense interest, it helps to understand precisely where the bottlenecks of conventional CAR-T manufacturing lie. The standard workflow begins with leukapheresis, in which a patient’s blood is circulated through an apheresis machine to harvest lymphocytes over several hours. Those cells must then be shipped to a centralized manufacturing facility, activated ex vivo with stimulation reagents, genetically modified to express the chimeric antigen receptor, expanded to therapeutic numbers over one to two weeks, subjected to quality control testing, cryopreserved or shipped fresh, and finally reinfused into the patient, typically after a lymphodepleting chemotherapy regimen designed to make space for the engineered cells. Each step introduces delays, costs, and opportunities for product failure. Patients with aggressive malignancies may progress or die while waiting, and manufacturing failures—caused by poor T cell yield, inadequate expansion, or contamination—affect a meaningful fraction of production runs. The review emphasizes that this model is fundamentally constrained by manufacturing capacity and healthcare resources, which is why only a small proportion of eligible patients worldwide actually receive approved CAR-T therapies despite their demonstrated efficacy.

The conceptual appeal of in vivo CAR-T is that it collapses this multi-week pipeline into a single administration event. Instead of removing T cells from the body, the delivery vehicle itself carries the genetic instructions encoding the chimeric antigen receptor to T cells circulating in blood, resident in lymphoid tissues, or infiltrating tumors. If the payload reaches enough of the right T cells, the patient’s own immune system becomes the manufacturing plant, producing CAR-expressing cytotoxic cells on site. The authors note that this strategy drastically reduces both time and cost, moving from weeks of ex vivo manipulation to practically immediate availability. Beyond logistics, there is a biological argument as well: T cells that are engineered while remaining in their native physiological environment may retain a less differentiated state than cells subjected to culture expansion. In particular, the review highlights the memory stem cell phenotype, a subset of T cells characterized by self-renewal capacity and the ability to generate durable effector populations. Ex vivo culture tends to push cells toward terminal effector differentiation, which correlates with shorter persistence after reinfusion. In vivo engineering, by contrast, could theoretically preserve this naive-like, long-lived compartment, potentially endowing the resulting CAR-T cells with superior persistence and anti-tumor durability.

Delivery technology sits at the heart of whether this vision can be realized, and the review organizes the current landscape into viral and non-viral platforms. On the viral side, targeted lentiviral vectors use engineered envelope proteins to bind specific receptors on T cells, redirecting tropism away from the broad cell types that wild-type lentiviruses can transduce. Lentiviruses offer two practical advantages: large genetic cargo capacity, which accommodates not just the CAR cassette but additional regulatory elements or multi-cistronic payloads, and stable genomic integration, which supports persistent receptor expression across cell divisions. The trade-off is that integration raises long-standing questions about insertional mutagenesis, the risk that the vector lands within or near a gene and disrupts its function. Engineered adeno-associated virus vectors take a different position on this spectrum. AAV genomes persist largely as episomes—circularized DNA molecules that remain separate from the host chromosomes—which substantially reduces insertional mutagenesis risk, though at the cost of more limited packaging capacity and, in some contexts, pre-existing immunity to common AAV serotypes in the human population.

Non-viral platforms are dominated by lipid nanoparticles, the same delivery class that proved itself in mRNA vaccines. LNPs encapsulate mRNA or other nucleic acid cargos within a lipid shell that can be modified on its surface with targeting ligands or tuned through optimized lipid composition to preferentially engage T cells. Because mRNA does not enter the nucleus and is degraded over days, expression is transient by design. The review points out that this transience avoids genotoxicity concerns entirely, and that LNP-mRNA approaches have already shown remarkable efficacy in non-tumor disease models, including cardiac fibrosis and systemic lupus erythematosus—findings that illustrate how a short pulse of CAR expression can be sufficient when the therapeutic goal is resetting a pathological immune process rather than eliminating a large tumor burden. Alongside LNPs, the review catalogs polymeric nanoparticles and virus-like particles as additional non-viral options, each offering different balances of loading capacity, safety profile, and manufacturing scalability.

The translational picture, while still early, is moving quickly. The authors report that both LNP-mRNA and targeted lentiviral systems have achieved efficient T cell transduction and deep target cell clearance in non-human primate models, an important step beyond rodent studies given the closer correspondence of primate immune systems and T cell biology to humans. In the clinic, early-phase trials for relapsed or refractory multiple myeloma and for autoimmune diseases have shown promising safety and preliminary efficacy. The inclusion of autoimmune indications is notable: B cell depletion, the same mechanism that underlies CAR-T therapy in certain leukemias and lymphomas, is being repurposed to reset the autoreactive immune repertoire in conditions such as lupus, where even transient CAR expression may produce durable remissions. This convergence of oncology and immunology applications reflects the broader thesis of the review—that in vivo CAR-T is not merely a cheaper version of existing therapy but a platform whose properties, particularly controllable expression duration, may suit different disease categories in different ways.

That controllability cuts both ways, and the review is candid about the central challenges. Persistence is the first: mRNA-based expression fades within days, which may be insufficient for complete tumor eradication in bulky or aggressive disease. The proposed solutions include circular RNA, whose covalently closed structure resists exonuclease degradation and can extend protein production, and self-amplifying RNA, which encodes its own replication machinery to prolong and amplify expression from a small initial dose. The second challenge is specificity. Off-target transduction—delivery vehicles reaching cells other than the intended T cell population—could create CAR-expressing cells that attack healthy tissue, while on-target effects such as cytokine release syndrome remain a concern even with correctly targeted cells. The review identifies logic-gated dual-recognition strategies, in which full T cell activation requires the simultaneous detection of two distinct antigens, and T cell-specific promoters that restrict receptor expression to the desired lineage, as critical engineering tools for narrowing these risks.

Immunogenicity presents a third obstacle, particularly acute for repeat dosing. Viral vectors and even lipid components can provoke immune responses that neutralize subsequent administrations, effectively converting a potentially titratable, redosable medicine into a one-shot therapy. Stealth vector design—engineering surfaces that evade immune surveillance—and transient immunomodulation to blunt anti-vector responses during the dosing window are the frontier solutions the authors highlight. Finally, there is the problem of the starting material itself. Unlike ex vivo manufacturing, where T cells can be selected, expanded, and quality-controlled before infusion, in vivo engineering must work with whatever T cells the patient possesses. In advanced cancer, patient T cells are often exhausted, functionally impaired by chronic antigen stimulation and an immunosuppressive tumor microenvironment. The review suggests cytokine pre-treatment to rejuvenate the T cell compartment and co-delivery of anti-exhaustion genes—genetic payloads that block inhibitory pathways or restore effector function—as strategies to make in vivo engineering effective even in immunologically compromised patients.

Looking ahead, the authors frame the field’s trajectory around several converging technologies. Artificial intelligence-assisted molecular design is expected to accelerate the optimization of delivery vehicles, targeting ligands, and payload architectures that would otherwise require exhaustive empirical screening. More precise T cell subset targeting aims to direct payloads not just to T cells generically but to specific subsets—memory stem cells, for instance—whose engineered progeny would have the most favorable persistence and safety profiles. Multi-target combination therapy addresses antigen escape, the well-documented phenomenon in which tumors downregulate a single target antigen and evade single-specificity CAR-T cells. Vector engineering tailored to the tumor microenvironment seeks to make delivered constructs responsive to local cues, such as hypoxia or inflammatory signals, so that CAR expression or activity is concentrated where it is needed. Taken together, the review positions in vivo CAR-T as a potential transition point for the entire cellular therapy field: a shift from individually manufactured living drugs toward scalable, off-the-shelf genetic medicines that could be stocked in clinics and administered on demand, dramatically expanding access to the patients whom current CAR-T manufacturing models have largely left waiting.

Subject of Research: In vivo CAR-T cell engineering and delivery strategies

Article Title: In vivo CAR-T therapy: From customized living drugs to universal genetic medicines

Article References: In vivo CAR-T therapy: From customized living drugs to universal genetic medicines. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: CAR-T therapy, in vivo T cell engineering, viral vectors, lipid nanoparticles, mRNA delivery, cancer immunotherapy, autoimmune disease, lentiviral vectors, adeno-associated virus, cell therapy, gene delivery, Immunity & Inflammation

The research team, led by Eilidh M. Duncan of Myeloma Patients Europe in Brussels, brought together an unusually diverse group of 38 participants to tackle the problem. Rather than consulting only clinicians or researchers, the investigators recruited patients with direct experience of CAR-T or bispecific antibody treatment, informal family carers, patient advocates from myeloma, lymphoma, and leukaemia communities, academic researchers, trialists, pharmaceutical industry representatives, and officials from regulatory and health technology assessment bodies, including the FDA and EMA. Data came from 14 one-to-one interviews with 16 participants and two online focus groups involving 15 and 19 participants respectively. Transcripts were analysed using a deductive-inductive thematic approach with double coding by independent researchers, a methodological rigor that strengthens the credibility of the resulting themes.

The technical context makes the challenge clear. CAR-T therapy involves engineering a patient’s own T cells to recognise cancer cells, while bispecific antibodies, or BsAbs, are laboratory-made molecules that physically link T cells to malignant cells. Both can trigger cytokine release syndrome, an immune overreaction causing fever, nausea, headache, low blood pressure, and potentially multi-organ failure. They can also cause immune effector cell-associated neurotoxicity syndrome, or ICANS, a neuropsychiatric condition ranging from mild tremor and confusion to haemorrhage, coma, and death. According to the study, CRS occurs in roughly 87 percent of CAR-T patients and 67 percent of those receiving BsAbs, while neurotoxicity affects 40 to 64 percent of CAR-T recipients, with 27 percent requiring intensive care admission. These acute toxicities typically emerge within one to four weeks after treatment, yet longer-term experiences are rarely assessed or reported.

One of the most striking findings concerns the logistical maze surrounding CAR-T treatment. Because the therapy is only available at specialised centres, patients frequently travel more than 100 kilometres for infusion and hospitalisation, then return to local providers for follow-up. This fragmentation across multiple treatment sites complicates PROM data capture and contributes to missing data. Participants also highlighted a sobering measurement paradox: patients experiencing the worst toxicities, such as cognitive impairment from ICANS or severe CRS, are often too unwell to complete questionnaires at all. As one researcher explained, the data dip between pre-lymphodepletion and week two captures only the sick patients who are still fit enough to fill out forms, not the sickest ones, making the reasons for missing data critically important to understand.

Bispecific antibodies present their own distinct measurement headache. Unlike CAR-T, which is a fixed-duration treatment, BsAbs involve continuous administration with a wide variety of side effects occurring over different time periods. Participants described agents such as talquetamab, a GPRC5D-targeting bispecific, which produces gastrointestinal effects, skin toxicity, complete taste loss, falling nails, itchy rashes, and weight loss. Some symptoms resolve over several months while others, like taste changes and weight loss, persist indefinitely. These treatment-specific domains fall outside the scope of generic instruments such as the EORTC QLQ-C30, which was designed for broad applicability rather than therapy-specific sensitivity. A recent review found 15 distinct PROMs used within just 16 CAR-T studies, highlighting the heterogeneity that undermines evidence synthesis across trials.

The timing of assessments emerged as a central controversy. Participants broadly agreed that baseline measurements for CAR-T and BsAbs trials should occur earlier than for older anticancer therapies, yet uncertainty persists about what baseline actually means. Because the CAR-T process spans several weeks, including leukapheresis, bridging therapies, and hospitalisation, a patient’s disease status and quality of life can shift dramatically between initial stages and infusion. Several researchers argued that future analyses should include two baselines, one right before lymphodepletion and one at the time of apheresis. Health technology assessment representatives insisted that baseline should mean study baseline, tied to treatment decision or randomisation, not any later time point.

Follow-up timing proved equally contentious. Participants suggested assessments as early as one week after infusion could serve as a crucial anchor point to capture the frequency, intensity, severity, and resolution of side effects. Industry representatives acknowledged the feasibility challenges, noting that patients are often hospitalised and facing severe complications like CRS shortly after infusion. For BsAbs with step-up dosing, where patients receive three doses during week one, some argued quality of life and toxicity should be explored after each individual dose. A regulatory representative called for weekly assessments during the first two months after CAR-T administration, using an item library to select really important symptoms such as headache and fatigue, alongside physical functioning measured on a high-frequency basis.

Perhaps the most emotionally resonant finding concerns what current PROMs systematically miss. Patients described the intense mental strain of waiting for CAR-T, including fear that their health would deteriorate during the manufacturing interval and render them ineligible. One patient recounted that doctors and nurses focused on physical side effects while never asking about the mental part, which was the most difficult aspect, and that her doctor essentially told her the mental part was hers to handle alone. Participants also flagged emerging concepts like time toxicity, meaning the time patients spend managing treatment and its effects, along with the burden on family carers, financial strain, and the psychological weight of living with an immunocompromised state. None of the three commonly used PROMs in trials, the EORTC QLQ-C30, MDASI-CAR, and PRO-CTCAE, capture waiting anxiety, logistical burden, caregiver burden, or treatment-free survival.

The study’s recommendations form a concrete blueprint for reform. The authors propose a dual-baseline strategy appropriate for rapid clinical changes preceding CAR-T infusion, mandated early high-frequency assessments, meaning weekly for the first four weeks, systematic inclusion of patient-important domains currently under-captured such as emotional well-being and time toxicity, continued PRO data collection beyond clinical progression, and transparent, comprehensive reporting of PRO findings. They also endorse interim strategies like combining instruments, adding PRO-CTCAE items to primary measures, and incorporating qualitative interviews or free-text responses. Longer-term, they support developing new treatment-specific PROMs, potentially with a modular core-plus-supplement design, alongside computerised adaptive testing to tailor questionnaires to individuals and reduce respondent burden.

The stakes extend far beyond academic measurement. CAR-T and BsAbs are high-cost therapies whose cost-effectiveness for health systems remains controversial, and PROM data directly informs reimbursement decisions. Under-reporting PRO data, the authors argue, is not just a concern for research validity but an unethical waste of patients’ time and energy, breaking the implicit agreement that patients’ contributions will meaningfully inform knowledge generation. Patients were willing to complete PROMs when they understood how their data would be used and felt confident it would not be wasted. As these immunotherapies continue to expand across haematological malignancies, the gap between what patients endure and what trials record can no longer be ignored. Clearer guidance from regulators and payers on instrument selection, assessment schedules, and reporting would substantially improve the quality and patient-centredness of evidence in this rapidly evolving field.

Subject of Research: Optimisation of patient-reported outcome measures for haematological cancer patients receiving CAR-T and bispecific antibody immunotherapies

Article Title: Optimisation of patient-reported outcome measurement for haematological cancer patients receiving novel immunotherapies: perspectives of multi-stakeholders

Article References: Duncan, E. M., Salviano, J., Kyriakou, C., Nier, S., Oerlemans, S., Salek, S., Morgan, K., & Joyner, K. (2026). Optimisation of patient-reported outcome measurement for haematological cancer patients receiving novel immunotherapies: perspectives of multi-stakeholders. Frontiers in Hematology, 5, Article 1800304. https://doi.org/10.3389/frhem.2026.1800304

Image Credits: AI Generated

DOI: 10.3389/frhem.2026.1800304

Keywords: CAR-T therapy, bispecific antibodies, patient-reported outcomes, PROMs, haematological malignancies, cytokine release syndrome, ICANS, quality of life, clinical trials, time toxicity, regulatory guidance, survivorship

The therapy works by harvesting a patient’s own T cells and engineering them to express a synthetic receptor that recognizes CD19, a surface protein found on B cells. Nearly all approved CD19 CAR-T products use a binding domain derived from the FMC63 antibody, which recognizes an epitope encoded by exons 3 and 4 of the CD19 gene. When cancer cells lose or alter the CD19 antigen, the engineered T cells have nothing to latch onto, and the malignancy escapes immune destruction. Previous work has shown that a splice variant called CD19Δexon2, in which exon 2 is skipped during RNA processing, is linked to therapy resistance and relapse. What has been missing is a reliable way to identify, before treatment ever begins, which patients carry this risk.

The research team, led by Søren Helweg Dam, Giorgia Moranzoni and Lars Rønn Olsen of the University of Copenhagen, together with colleagues at the Technical University of Denmark, Rigshospitalet and Odense University Hospital, took a computational approach. They mined publicly available RNA-sequencing data from four B-ALL patients treated with CD19 CAR-T therapy—one complete responder, one non-responder, and two who relapsed after an initial response. For each patient, they quantified the percent spliced in (PSI) of CD19 exon 2, a metric that estimates how much of the CD19 messenger RNA retains exon 2 versus skipping it. A lower PSI means a higher abundance of the CD19Δexon2 variant.

The pattern was striking. The patient who relapsed earliest—just 1.5 months after infusion—had the lowest pre-treatment exon 2 PSI, with 21 RNA reads spanning the exon 1–3 junction, a direct signature of exon 2 skipping. The non-responder showed 13 such reads, the slow relapser only one, and the complete responder none at all. After treatment, CD19 read coverage dropped sharply in all patients who initially responded, consistent with effective B-cell depletion, while the non-responder retained substantial CD19 expression and continued exon 1–3 junction usage. Although the cohort is far too small for statistical inference, the qualitative concordance between exon 2 inclusion and clinical outcome suggests that reduced exon 2 retention may be associated with CAR-T therapy failure.

To understand why skipping exon 2 might undermine the therapy, the researchers turned to structural modeling. They retrieved the experimentally resolved structure of canonical CD19 from the AlphaFold Database and predicted the structure of the Δexon2 variant de novo using AlphaFold3. In the canonical protein, the two discontinuous segments of the FMC63 epitope fold into close spatial proximity, forming a contiguous binding surface. Exon 2 skipping disrupts this arrangement, separating the epitope elements and likely impairing antibody accessibility. The finding provides a plausible mechanistic explanation for the experimentally observed reduction in FMC63 binding affinity to the variant protein, positioning exon 2 as a stabilizing element of the functional epitope.

Experimental studies add weight to this model. CD19 isoforms lacking exon 2 exhibit defective folding, abnormal glycosylation, and impaired interaction with the CD81 chaperone complex, causing the misfolded protein to be retained in the endoplasmic reticulum rather than trafficked to the cell surface. Only a small fraction of the variant escapes quality control and reaches the membrane, and that population appears unstable and poorly recognized by CD19-directed antibodies. Reduced CAR recognition of CD19Δexon2 therefore arises from both impaired trafficking and altered surface conformation, leading to markedly diminished antigen density.

Perhaps the most provocative finding is that exon 2 skipping is not exclusively a therapy-induced phenomenon. The team analyzed larger RNA-sequencing datasets from treatment-naïve B-ALL (75 samples from the iCOPE/STAGING study), newly diagnosed DLBCL (553 samples from the GOYA trial), and healthy tissues from the GTEx project (1,048 blood and 255 spleen samples). Exon 2 inclusion was uniformly high in B-ALL and healthy tissues, with median PSI values of 96.3 percent, 96.9 percent and 97.7 percent respectively, and roughly 96 to 97 percent of samples in these groups showed near-complete exon retention. DLBCL, by contrast, displayed marked heterogeneity: the median PSI was 91.6 percent, only 59.5 percent of samples met the 90 percent inclusion threshold, and 86.8 percent showed measurable skipping, including one patient with a PSI as low as 22.8 percent.

These results suggest that CD19Δexon2 is a naturally occurring, low-frequency splice variant present in both malignant and normal B cells, rather than a strictly disease-specific or therapy-induced transcript. Under the selective pressure of CD19-directed CAR-T therapy, malignant cells already expressing the variant may gain a survival advantage and expand, producing the apparent enrichment of the isoform in relapsed disease. This reframes the biology: the variant is not created by the treatment but unmasked by it, which is precisely what makes pre-treatment detection potentially valuable.

The translational implications are considerable. Because bulk RNA sequencing of leukemic cells is increasingly performed as part of the diagnostic workup for B-ALL, exon 2 PSI could be computed as an additional feature at no extra experimental cost. Alternatively, quantitative PCR assays targeting the exon 1–3 junction could provide a rapid and inexpensive test to stratify relapse risk or monitor splicing changes during follow-up. The epitope connection may extend even further: the parental antibody of blinatumomab, a bispecific T-cell engager now moving into front-line B-ALL therapy, competes with FMC63 for CD19 binding, suggesting that structural disruption caused by exon 2 skipping could also compromise blinatumomab-mediated cytotoxicity—though this remains to be formally tested.

The authors are careful to emphasize the limitations. The CAR-T cohort contains only four patients, precluding statistical analysis and any claim of causality or predictive value. Post-treatment samples had sparse read coverage, bulk RNA-seq cannot resolve whether the variant is co-expressed with canonical CD19 in the same cells or confined to distinct subclones, and pre-treatment tumor burden may confound PSI measurements, since normal B cells express predominantly canonical CD19. Protein-level consequences remain to be verified experimentally, and the structural analyses rely on computational modeling. Still, the consistency between structural predictions, patient-level RNA patterns and baseline tissue distributions strengthens the biological plausibility of the findings, and larger prospective studies using targeted long-read sequencing or isoform-specific qPCR could determine whether CD19 exon 2 skipping is merely a correlate of poor response or a functional determinant of resistance. Either outcome would sharpen the understanding of CD19 biology and help clinicians decide which patients might benefit most from multi-target CAR strategies directed against CD19 together with CD20 or CD22.

Subject of Research: CD19 exon 2 alternative splicing as a potential prognostic biomarker for relapse after anti-CD19 CAR-T cell therapy in B-cell malignancies

Article Title: CD19 exon 2 skipping is a potential prognostic correlate of anti-CD19 CAR-T therapy relapse

Article References: Dam, S. H., Moranzoni, G., Høie, M. H., Modvig, S., Wadt, K. A. W., Als-Nielsen, B., Schmiegelow, K., Vitting-Seerup, K., Barnkob, M. B., & Olsen, L. R. (2026). CD19 exon 2 skipping is a potential prognostic correlate of anti-CD19 CAR-T therapy relapse. Frontiers in Molecular Medicine, 6, Article 1763390. https://doi.org/10.3389/fmmed.2026.1763390

Image Credits: AI Generated

DOI: 10.3389/fmmed.2026.1763390

Keywords: CAR-T therapy, CD19, alternative splicing, exon 2 skipping, B-cell acute lymphoblastic leukemia, DLBCL, relapse, biomarker, antigen escape, FMC63 epitope, RNA sequencing, immunotherapy resistance

The biological logic behind B-cell depletion in lupus is compelling. At the heart of the disease lies a breakdown of self-tolerance, with polyclonal activation of B cells that differentiate into plasmablasts and plasma cells churning out autoantibodies. These antibodies bind self-antigens to form immune complexes, which deposit in the kidneys, joints, and skin, activating the complement cascade and driving progressive organ damage. Lupus B cells are also quantitatively and qualitatively abnormal: they overproduce pro-inflammatory cytokines such as tumor necrosis factor, interleukin-6, and interferon-gamma, present autoantigens to T cells in a self-perpetuating activation loop, and are further stimulated when their toll-like receptors engage nucleic acid-protein complexes, the most prominent autoantigens in the disease. Striking at this cellular linchpin, the authors argue, is a rational therapeutic strategy.

Rituximab itself is a chimeric monoclonal antibody, part murine variable region and part human constant region, assembled as an immunoglobulin G1 molecule directed against CD20, a surface marker found on pre-B and mature B cells. Its principal killing mechanism is complement-dependent cytotoxicity, which classifies it as a type I anti-CD20 antibody. Recent structural work has added molecular texture to that picture: researchers solved the structure of CD20 bound to rituximab, revealing a compact double-barrel dimer gripped by two antibody antigen-binding fragments. That architecture suggests rituximab cross-links CD20 into circular assemblies within lipid rafts, a clustering event thought to supercharge complement activation at the cell surface.

The clinical record, however, is more complicated than the biology. Two pivotal randomized, placebo-controlled trials, EXPLORER in extrarenal lupus and LUNAR in lupus nephritis, both missed their primary endpoints, casting a long shadow over the drug. The review’s authors dissect why those trials may have failed on design rather than biology. EXPLORER lumped together heterogeneous disease manifestations, making uniform improvement hard to demonstrate, and both trials layered rituximab on top of intensive background immunosuppression, including high-dose corticosteroids and, in LUNAR, 3 grams per day of mycophenolate mofetil, regimens robust enough to mask any added benefit. The endpoints were also stringent and arguably ill-suited to capturing partial responses, and both trials judged efficacy at 52 weeks, an early timepoint in a disease where clinical responses often take longer to mature. Both trials did confirm that rituximab reliably depletes peripheral B cells, even when that depletion did not translate into measured clinical improvement.

Real-world experience tells a very different story. Observational studies and registries, encompassing cohorts from 18 to 261 patients, have consistently reported response rates between roughly 60 and 85 percent when rituximab is added to standard care in refractory disease. Follow-up periods in these studies range from six months to five years, with only one study extending beyond a decade, a small real-world analysis that documented disease activity improvements persisting at ten years or more. The evidence base is admittedly messy: endpoints vary from clinician judgment to BILAG and SELENA-SLEDAI activity scores, dosing schemes differ across and even within studies, and most analyses lack control groups. Yet the consistency of benefit across so many heterogeneous settings has made rituximab a mainstay for patients whose disease has shrugged off conventional therapy, and scientific society guidelines now sanction its use in refractory SLE.

Nowhere is that benefit clearer than in lupus nephritis, the kidney complication that afflicts roughly 60 percent of patients and can progress to end-stage kidney disease. A Bayesian meta-analysis found that ESKD risk in lupus nephritis fell from the 1970s to the mid-1990s, plateaued, and then paradoxically rose again in the late 2000s despite escalating immunosuppression. Against that trend, the steroid-sparing RITUXILUP protocol stands out: 50 patients received two 1-gram rituximab infusions with limited methylprednisolone and mycophenolate maintenance but no oral steroids, achieving complete and partial renal responses in 52 and 34 percent at 52 weeks. Long-term follow-up of that regimen showed preserved renal function beyond five years. A pooled European analysis of 164 patients with biopsy-proven nephritis found the highest complete response rates in class III and mixed disease, roughly 62 and 50 percent, and the lowest in class IV and pure class V, while nephrotic syndrome and renal failure at treatment initiation predicted worse outcomes. A network meta-analysis ranked rituximab and tacrolimus as the most efficacious induction agents for lupus nephritis.

The stakes of achieving renal response are enormous. Ten-year renal survival reaches 95 percent in patients who achieve a complete response, 45 percent with partial response, and just 19 percent with no response; at 15 years, chronic kidney disease-free survival is 95.2, 87.6, and 55.4 percent respectively. An early proteinuria drop below 0.8 grams per day at 12 months is the best predictor of seven-year renal survival, and each renal flare adds to irreversible damage. Intriguingly, a small biopsy study in membranous lupus nephritis showed that immune complex resorption increased significantly after rituximab but not after conventional immunosuppression, with all seven rituximab-treated patients responding compared with 53 percent of conventionally treated controls, hinting at histological benefit beyond proteinuria numbers.

Perhaps the review’s most provocative thread concerns timing. Data from 131 patients showed that those needing only a single rituximab cycle had multi-organ but non-refractory disease and far less prior immunosuppressive exposure, while patients previously treated with azathioprine or methotrexate were significantly more likely to require repeated cycles. A multicenter study of 147 patients found treatment failure in 27 percent at six months, with fewer prior immunosuppressants and higher complement C4 levels protecting against failure. In newly diagnosed patients, early rituximab plus cyclophosphamide produced dramatic BILAG score reductions and slashed cumulative prednisolone doses, with seven-year follow-up showing 2.63 mean flares versus 4 in controls and cumulative steroid exposure of roughly 4,746 milligrams versus 12,554. A retrospective study of newly diagnosed patients found modified lupus low disease activity state in 76 percent of first-line rituximab recipients versus 45.8 percent on conventional first-line therapy. A dedicated clinical trial, FIRST, now underway in 128 patients aged five and older with new moderate-to-severe lupus, will randomize early rituximab against placebo on top of standard care to test whether prompt B-cell depletion can genuinely rewrite the disease trajectory.

Safety data offer reassurance with caveats. Infusion reactions range from 3.5 to 16.4 percent in most cohorts, though some report up to 44 percent; infections occur in 40 to 57 percent of patients, with serious infections requiring hospitalization in 7 to 20 percent, most commonly respiratory and urinary tract infections and herpes zoster. Mortality is low, 0 to nearly 3 percent, mostly from severe infection. A network meta-analysis found rituximab carried the lowest serious adverse event rate among B-cell-targeting biologics, with anifrolumab showing the lowest infection likelihood at 78.7 percent ranking probability followed by rituximab at 72.6. Hypogammaglobulinemia after repeated cycles remains uncommon, affecting 21 percent for IgM and 7 percent for IgG, though rituximab-treated patients face heightened COVID-19 severity and mortality. Low-dose regimens, two 200-milligram infusions or 100 milligrams weekly for four weeks, have shown encouraging response rates in lupus-related thrombocytopenia and lupus enteritis, potentially trimming both toxicity and cost.

The therapeutic landscape around rituximab is shifting rapidly. Obinutuzumab, a glycoengineered type II anti-CD20 antibody that kills B cells through antibody-dependent cellular phagocytosis rather than complement, has been FDA-approved for active lupus nephritis after the REGENCY trial, and small series show it rescuing patients with secondary non-response to rituximab, with median SLEDAI-2K scores falling from 16 to 5 at six months. Ofatumumab and ocrelizumab offer fully human or humanized alternatives with lower immunogenicity, though their phase III lupus programs stumbled on infections and lack of efficacy. Belimumab after rituximab eliminates severe flares and works best, exploratory data suggest, in patients with high baseline serum IgA2 anti-dsDNA antibody concentrations, a potential biomarker for personalized sequencing. And at the frontier, allogeneic CD19-targeted CAR-T cell therapy has induced durable, drug-free remission in refractory lupus, albeit at enormous cost and with risks including cytokine release syndrome and prolonged B-cell aplasia. For now, the review concludes, rituximab’s accessibility, two decades of safety experience, and biosimilar-driven affordability keep it central to lupus care, even as deeper depletion strategies wait in the wings.

Subject of Research: The role of rituximab, an anti-CD20 B-cell-depleting antibody, in therapeutic strategies for systemic lupus erythematosus

Article Title: Positioning rituximab in the therapeutic strategies for SLE

Article References: Staveri, C., & Liossis, S.-N. C. (2026). Positioning rituximab in the therapeutic strategies for SLE. Frontiers in Lupus, 4, Article 1877692. https://doi.org/10.3389/flupu.2026.1877692

Image Credits: AI Generated

DOI: 10.3389/flupu.2026.1877692

Keywords: rituximab, systemic lupus erythematosus, lupus nephritis, B-cell depletion, anti-CD20, belimumab, obinutuzumab, CAR-T therapy, autoimmunity, refractory disease, biologic therapy, rheumatology

The scale of the problem is expanding rapidly. As cellular therapies and B-cell-depleting agents become standard care for hematologic malignancies, the number of patients with prolonged hypogammaglobulinemia, meaning abnormally low levels of immunoglobulin G, is expected to rise substantially. These patients suffer recurrent bacterial infections, frequent hospitalizations and a marked decline in health-related quality of life. The immune dysfunction is not uniform: B-cell-depleting drugs primarily damage humoral immunity, while stem cell transplantation and CAR-T therapy can produce broader defects that also impair cellular immune defenses and delay immune reconstitution for months or even years. Because diagnostic criteria developed for primary antibody deficiencies do not translate cleanly to these acquired conditions, clinicians must tailor immunoglobulin replacement to each patient’s infection history, immune status and treatment regimen.

The evidence that replacement therapy works is robust. Real-world data and clinical studies consistently show substantial reductions in infections, emergency department visits and hospital admissions once therapy begins. In the Ontario Immunoglobulin Treatment Case Registry, treatment was associated with an 82.6 percent reduction in annual infections, an 84.6 percent reduction in emergency department visits and an 83.3 percent reduction in hospitalizations. A Japanese retrospective cohort of patients with hematologic malignancy-associated hypogammaglobulinemia found that 20 percent subcutaneous immunoglobulin cut infection rates from 3.67 to 1.32 infections per patient-year. Post-marketing data for the subcutaneous product IgPro20 showed similar reductions in infections and serious bacterial events. Randomized trials and consensus guidelines support both routes for infection prevention in chronic lymphocytic leukemia, lymphoma and post-transplant populations.

The two delivery routes differ fundamentally in their pharmacokinetic behavior. Intravenous immunoglobulin is typically given every three to four weeks in a hospital or infusion center, producing a sharp peak in serum IgG followed by a gradual decline toward a trough before the next infusion. Subcutaneous immunoglobulin, by contrast, is administered more frequently, often weekly or biweekly, and sometimes monthly with facilitated formulations, yielding near-steady-state IgG concentrations with minimal peak-to-trough fluctuation. This smoother exposure profile matters clinically, because trough levels are a central pharmacokinetic goal of long-term management. Notably, a retrospective comparison of 131 patients with secondary antibody deficiency and 102 with primary antibody deficiency found that the secondary group achieved comparable reductions in infection burden despite receiving lower doses and reaching lower steady-state IgG trough concentrations, suggesting that dosing requirements differ between the two populations.

Safety profiles also diverge in clinically meaningful ways. Intravenous immunoglobulin carries a higher incidence of systemic adverse reactions, including headache, fever, nausea, thromboembolic events, aseptic meningitis, hemolysis and, less commonly, renal dysfunction or anaphylaxis. Systemic reactions occur in roughly 20 to 50 percent of patients and in 5 to 15 percent of infusions, although most are mild to moderate. Subcutaneous administration produces far fewer systemic events but more frequent local injection-site reactions such as erythema, swelling and rash, which are typically mild and self-limited. Facilitated subcutaneous immunoglobulin, which includes an added enzyme that allows larger volumes to be infused, may further improve tolerability while reducing hospital burden, according to emerging evidence reviewed by the authors.

Beyond infection control, the review highlights patient-reported outcomes as an increasingly important dimension of treatment success. Real-world studies show that subcutaneous therapy is associated with greater treatment convenience, improved autonomy and better quality-of-life scores, largely because patients can self-administer at home rather than traveling to infusion centers. Patients who switch from intravenous to subcutaneous treatment frequently report higher satisfaction and a reduced treatment burden. These gains in daily living are not merely cosmetic: they translate into measurable differences in how immunocompromised cancer survivors experience long-term supportive care.

Health economics reinforce the case for the subcutaneous route. A ten-year cost-utility analysis comparing hospital-based intravenous therapy with home-based subcutaneous therapy found that the subcutaneous approach yielded more quality-adjusted life years, 3.51 versus 3.07, at lower cumulative healthcare cost, making it the dominant strategy from a healthcare system perspective. Home-based administration reduces infusion-center utilization and hospital visits while maintaining clinical effectiveness, and registry data demonstrate durable treatment persistence during long-term subcutaneous therapy in routine practice. As global demand for plasma-derived immunoglobulin continues to climb, the review argues that responsible stewardship of this finite resource requires evidence-informed patient selection, periodic reassessment and timely discontinuation when immune recovery makes replacement unnecessary.

Guidance from major international bodies, including the American Academy of Allergy, Asthma, and Immunology, the British Committee for Standards in Hematology, the National Comprehensive Cancer Network and the European Society for Immunodeficiencies, supports either route for patients with documented hypogammaglobulinemia and recurrent or severe infections. The AAAAI recommends an individualized intravenous dosing range of 0.4 to 0.8 grams per kilogram every 28 days when clinically indicated. In practice, therapy is generally considered for patients with chronic lymphocytic leukemia or multiple myeloma whose IgG levels fall below roughly 400 to 500 milligrams per deciliter and who experience recurrent or severe infections despite appropriate antimicrobial management. Inadequate vaccine responses to diphtheria, tetanus or pneumococcal antigens can further support initiation in selected patients. For stem cell transplant recipients, routine prophylactic intravenous immunoglobulin is not recommended, but either route may be considered when IgG remains below 400 milligrams per deciliter with recurrent or severe infections. After CAR-T therapy, baseline immune assessment and individualized replacement strategies are increasingly advised.

The review emphasizes that there is no universally accepted IgG trough target for this population. Decisions to start, continue, modify or stop therapy should integrate serum IgG concentrations with infection history, underlying disease activity, ongoing immunosuppression and evidence of B-cell reconstitution rather than relying on a single numeric threshold. Monitoring should track infection frequency and severity, adverse events, treatment tolerability and, following B-cell-directed therapy, peripheral B-cell recovery assessed by flow cytometry when appropriate. Patients who remain infection-free and show immune recovery may interrupt or discontinue therapy, with reinitiation if infections recur, although validated biomarker thresholds for stopping treatment have not been established. The primary objective, the authors stress, is prevention of recurrent and severe infections, not achievement of a universal serum IgG number.

Significant gaps remain. Comparative prospective data on subcutaneous versus intravenous therapy in hematologic malignancy populations, particularly among CAR-T and transplant recipients, are scarce, and evidence on survival benefits is limited because most studies were not powered to detect mortality differences. Replacement therapy also addresses only humoral deficiency and cannot correct the broader cellular immune dysfunction that follows transplantation or CAR-T treatment. Several ongoing trials, including registries of facilitated subcutaneous immunoglobulin in multiple myeloma and a dedicated study of immunoglobulin for hypogammaglobulinemia after CAR-T therapy, should help refine dosing, monitoring and discontinuation criteria. For now, the message for clinicians is clear: both routes work, but for patients facing years of antibody replacement, the steadier pharmacokinetics, fewer systemic reactions and home-based convenience of the subcutaneous route make it an increasingly attractive first choice.

Subject of Research: Immunoglobulin replacement therapy via subcutaneous and intravenous routes for secondary immunodeficiency in hematologic malignancy patients

Article Title: Immunoglobulin replacement therapy in hematologic malignancy–associated secondary immunodeficiency: roles of SCIG and IVIG

Article References: Seaquist, E., Majapuro-Hirvonen, A., Van Wagoner, R., & Rutland, B. (2026). Immunoglobulin replacement therapy in hematologic malignancy–associated secondary immunodeficiency: roles of SCIG and IVIG. Frontiers in Hematology, 5, Article 1904290. https://doi.org/10.3389/frhem.2026.1904290

Image Credits: AI Generated

DOI: 10.3389/frhem.2026.1904290

Keywords: immunoglobulin replacement therapy, secondary immunodeficiency, hematologic malignancies, SCIG, IVIG, CAR-T therapy, hypogammaglobulinemia, immune reconstitution, infection prevention, pharmacokinetics, patient-reported outcomes, healthcare cost-effectiveness

The study enrolled fourteen patients with B-cell acute lymphoblastic leukemia that had relapsed after allogeneic stem-cell transplantation. Eight of the fourteen carried extramedullary disease, the most difficult manifestation to treat. Rather than harvesting each patient’s own T cells for engineering—a standard approach in autologous CAR-T therapy—the team used allogeneic CAR-T cells, meaning the engineered immune cells were derived from donor sources. This distinction matters enormously in the post-transplant setting. Patients who have already undergone a stem-cell transplant often have depleted, dysfunctional T cells after years of chemotherapy, immunosuppression, and marrow failure, making it difficult or impossible to manufacture a potent autologous product. Allogeneic products sidestep that problem, but they introduce their own hazards: the infused donor cells can attack the recipient’s healthy tissues, and the recipient’s immune system can reject the therapeutic cells before they do their work.

The results, with a median follow-up of 13.8 months and individual follow-ups extending to nearly four and a half years, were striking. Thirteen of the fourteen patients—92.9 percent—achieved a complete remission, and the median duration of remission reached 12.7 months, with the longest remission lasting more than fifty months. Among the eight patients with extramedullary disease, seven achieved complete remission, a rate of 87.5 percent, with a median duration of remission of 14.7 months. Remarkably, the patients with disease outside the marrow did not fare worse than the cohort as a whole; their remissions were, if anything, slightly more durable on average. Neither median overall survival nor median event-free survival had been reached in either the overall cohort or the extramedullary subgroup at the time of analysis, meaning that more than half of the patients in both groups were still alive and free of events when the data were cut.

The technical logic behind targeting CD19 is central to understanding why this approach works. CD19 is a surface protein expressed on virtually all B-lineage cells, including the malignant lymphoblasts of B-ALL, but it is absent from nearly all other tissues, making it an attractive bullseye. CAR-T cells are engineered with a chimeric antigen receptor—a synthetic molecule combining an antibody-derived single-chain variable fragment that recognizes CD19 with intracellular signaling domains that activate the T cell upon binding. When the engineered cells encounter CD19 on a leukemia cell, they are triggered to kill it and to proliferate, amplifying the attack. In this study, the researchers tracked the kinetics of the infused cells in patients’ blood, finding that the CAR-T cells persisted in vivo for a median of 5.9 months, with persistence ranging from 1.2 to 51.6 months. That sustained presence is thought to underpin the durability of the remissions, as the cells continue to patrol for any leukemia cells that escape initial clearance.

Extramedullary disease has historically been a weak point for CAR-T therapy of any kind. Solid tumor deposits outside the marrow and blood present a different microenvironment, one that may suppress T-cell infiltration and function, and leukemia cells sequestered in such sanctuaries can evade surveillance. The finding that seven of eight patients with extramedullary disease achieved complete remission challenges the assumption that this population should be excluded from CAR-T strategies or expected to respond poorly. The authors suggest that allogeneic CAR-T therapy could serve as an effective backbone onto which tailored combination strategies can be built—for example, pairing the cellular therapy with targeted drugs in patients whose leukemia carries specific driver mutations.

That combination concept is not hypothetical in this cohort. Four of the eight patients with extramedullary disease had Philadelphia chromosome-positive leukemia, an aggressive subtype defined by the BCR-ABL fusion gene, and they received maintenance therapy with tyrosine kinase inhibitors after their CAR-T infusions. One patient received dasatinib, two received ponatinib, and one received olverembatinib, a newer third-generation inhibitor developed in China specifically for resistant Philadelphia-positive leukemias. The rationale is straightforward: CAR-T cells clear CD19-expressing leukemia cells rapidly, while tyrosine kinase inhibitors suppress the oncogenic signaling that drove the leukemia in the first place, attacking the disease through a complementary mechanism and potentially preventing outgrowth of CD19-negative escape variants. Whether this sequencing improves long-term outcomes will require larger controlled studies, but the durable remissions observed in these patients provide a proof of concept.

Safety is where allogeneic CAR-T therapy has historically stumbled, and the toxicities observed here deserve close attention. One patient experienced grade 3 cytokine release syndrome, the systemic inflammatory storm caused by massive immune activation, and grade 4 immune effector cell-associated neurotoxicity syndrome, a potentially life-threatening neurological complication of CAR-T therapy. Both grades represent the severe end of the toxicity spectrum, though such events are generally manageable with intensive supportive care, the interleukin-6 blocker tocilizumab, and corticosteroids. In addition, one patient developed acute graft-versus-host disease affecting the gastrointestinal tract, followed by chronic graft-versus-host disease involving the skin and lungs—a reminder that donor-derived immune cells can turn against host tissues, the very risk that makes allogeneic products controversial. The authors characterize the overall safety profile as manageable, and notably, graft-versus-host disease occurred in only one of fourteen patients, suggesting that the product design or the post-transplant immune context may mitigate this risk compared with earlier allogeneic platforms.

The engineering details of allogeneic CAR-T products are critical to those safety outcomes. Because donor T cells carry their own T-cell receptors, they can recognize recipient tissues as foreign and initiate graft-versus-host disease. Strategies to prevent this include knocking out or disrupting the endogenous T-cell receptor, using short hairpin RNA or gene-editing techniques to silence the molecules responsible, and selecting donor sources that minimize alloreactivity. The study’s product, manufactured by Shanghai Unicar-Therapy Bio-Medicine Technology, was used under a clinical trial registered with the Chinese Clinical Trial Registry in August 2020. Two of the study’s authors are employees of the manufacturing company; the remaining authors declared no conflicts of interest, and the work was funded by the National Natural Science Foundation of China and other national and provincial research programs. The study was approved by the institutional review board of The Third Xiangya Hospital, and all patients provided written informed consent.

The broader significance of the work lies in its positioning within the CAR-T treatment landscape. Autologous anti-CD19 CAR-T therapy has transformed the management of relapsed and refractory B-cell malignancies, but its application after allogeneic transplant has been constrained by manufacturing failures, poor T-cell quality, and concerns about exacerbating graft-versus-host disease. Demonstrating that a donor-derived product can achieve a 92.9 percent complete remission rate with controllable toxicity in precisely this population reframes the calculus. It suggests that patients who relapse after transplant need not be relegated to palliative care or high-risk salvage chemotherapy; they may be candidates for a second, engineered immune attack using cells that are themselves of donor origin, effectively recruiting a fresh immunological army against the leukemia.

Caveats remain, and the authors are careful not to overstate them away. Fourteen patients constitute a small, single-center cohort, and the trial was retrospectively registered, limitations that temper the strength of any conclusion. Median survival figures that have not been reached are encouraging but reflect a relatively short median follow-up of under fourteen months. Longer observation will be needed to determine how many remissions endure and whether late relapses, CD19 loss, or delayed toxicities emerge. Still, for a disease setting in which historical survival is measured in months, the combination of near-universal remission induction, multi-year remissions in some patients, and tolerable toxicity represents a genuine advance. The study points toward a future in which allogeneic CAR-T cells, deployed as a rapid and repeatable platform and combined rationally with targeted agents, become a standard salvage strategy for the hardest-to-treat relapses of childhood and adult acute lymphoblastic leukemia.

Subject of Research: Allogeneic anti-CD19 CAR-T cell therapy for B-cell acute lymphoblastic leukemia relapsed after allogeneic stem-cell transplantation

Article Title: Allogeneic anti-CD19 CAR-T therapy demonstrates sustained efficacy and manageable safety in post-allo-HSCT relapsed B-ALL with extramedullary disease

Article References: Liu, R., Zhang, J., Li, Y., Wang, E., Xiao, H., Chen, X., Yan, Y., Wang, L., Tang, Y., Kang, L., Yu, L., Cheng, Q., & Li, X. (2026). Allogeneic anti-CD19 CAR-T therapy demonstrates sustained efficacy and manageable safety in post-allo-HSCT relapsed B-ALL with extramedullary disease. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-026-04585-8

Image Credits: AI Generated

DOI: 10.1007/s00262-026-04585-8

Keywords: CAR-T therapy, allogeneic CAR-T, B-cell acute lymphoblastic leukemia, CD19, extramedullary disease, allogeneic hematopoietic stem-cell transplantation, relapse, graft-versus-host disease, cytokine release syndrome, tyrosine kinase inhibitors, Philadelphia chromosome, immunotherapy

The research, led by Jan-Michel Heger of University Hospital Cologne together with colleagues from centers across Germany and Austria, set out to validate which variables are clinically relevant prognostic factors and which act as treatment-effect modifiers in DLBCL. The distinction is technically crucial. A prognostic factor predicts how patients fare overall regardless of which therapy they receive, such as advanced age or high tumor burden. A treatment-effect modifier, by contrast, changes how well a specific therapy works, meaning the treatment’s benefit itself differs depending on the patient’s status. Confusing the two can distort indirect treatment comparisons, the family of statistical methods, including matching-adjusted and simulated treatment comparisons, that health technology assessment bodies increasingly rely on when randomized evidence is absent. If an effect modifier is left unadjusted, the comparison may attribute differences in outcome to the drug when they actually stem from the patient mix.

To build the variable list, the team first drew on a prior systematic literature review of prognostic factors for efficacy and safety outcomes of CAR-T therapy in DLBCL, then refined the candidates through clinical review. Six experienced hematologists and oncologists from Germany and Austria, institutions spanning Cologne, Berlin, Essen, and Vienna, then participated in a structured, two-round expert elicitation process modeled on consensus methodologies such as the Delphi approach. Each expert rated the importance of every candidate variable as a prognostic factor, a treatment-effect modifier, or both, using a three-point Likert scale. Variables that crossed predefined consensus thresholds were assigned to relevance tiers and then mapped to specific clinical endpoints: progression-free survival, overall survival, response outcomes, and CAR-T-related toxicities such as cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome, the two signature adverse events of this therapeutic class.

The findings on prognostic factors were remarkably coherent. Thirteen variables reached the top relevance tier: Eastern Cooperative Oncology Group performance status, age, disease histology, the International Prognostic Index, disease stage, elevated lactate dehydrogenase, bulky disease, extranodal involvement, tumor burden, primary refractory disease, number of relapses, time to relapse, and the number of prior lines of therapy. Six of these achieved unanimous agreement among all panelists as prognostic factors for survival outcomes: ECOG performance status, the IPI, disease histology, disease stage, elevated LDH, and primary refractory disease. These are, for the most part, the venerable workhorses of lymphoma prognostication. The IPI, developed in the early 1990s, combines age, performance status, stage, LDH, and extranodal sites into a single risk score, and its components dominated the panel’s top tier, suggesting that decades of clinical experience have produced a stable, shared understanding of what drives outcomes in aggressive B-cell malignancy.

The logic behind each variable is biologically plausible. ECOG performance status captures a patient’s functional fitness, which influences both tolerance of intensive lymphodepleting chemotherapy before CAR-T infusion and the ability to survive complications. Elevated LDH signals high tumor turnover and burden. Primary refractory disease, meaning lymphoma that never responded to initial therapy, and short time to relapse both mark biologically aggressive, treatment-resistant clones. Number of prior therapy lines reflects cumulative exposure to cytotoxic regimens and often correlates with diminishing responsiveness. Bulky disease and high tumor burden strain not only efficacy but also safety, a point the panel emphasized: tumor burden-related variables were judged important for both efficacy endpoints and toxicity outcomes, including the risk of cytokine release syndrome, in which engineered T cells trigger a systemic inflammatory cascade, and neurotoxicity, which can range from mild confusion to life-threatening cerebral edema.

Where consensus weakened was precisely where the science is least mature: treatment-effect modifiers. Compared with the strong agreement on prognostic factors, substantially lower agreement emerged for effect modifiers, particularly for response-based outcomes such as complete response and overall response rates. Only a handful of variables reached the top tier as effect modifiers: primary refractory disease, time to first relapse, best response to prior therapy, bridging therapy, CAR-T product type, and CAR-T-related response characteristics. Bridging therapy, the treatment given between leukapheresis, when a patient’s T cells are harvested for engineering, and infusion of the final CAR-T product, was the sole modifier to achieve unanimous agreement for complete and overall response rates. That makes intuitive sense: bridging therapy both controls disease during the manufacturing window and may itself select for or against certain patient profiles, entangling its effect with the therapy being evaluated.

The asymmetry between prognostic factors and effect modifiers is not a failure of the panel but a reflection of the evidence base. Identifying a prognostic factor requires only observing that outcomes vary with a characteristic; identifying an effect modifier requires evidence that the magnitude of a treatment’s benefit differs across levels of that characteristic, which demands comparative data that are often simply unavailable. Recent real-world analyses comparing tisagenlecleucel and axicabtagene ciloleucel, the two most widely used CD19-directed CAR-T products in DLBCL, have begun to probe such interactions, but the literature remains thin and heterogeneous. The panel’s hesitancy, in other words, encodes genuine scientific uncertainty rather than disagreement about method. For analysts constructing indirect comparisons, this means adjustment strategies for effect modification must be justified case by case, with sensitivity analyses exploring how conclusions change under different assumptions.

The study’s methodology also carries lessons for the broader field of comparative effectiveness research. Structured expert elicitation has become an accepted tool when empirical data cannot settle a question, and the two-round design with predefined consensus thresholds guards against the dominance of a single loud voice. The approach mirrors frameworks developed by health technology assessment bodies, including the German Institute for Quality and Efficiency in Health Care, which has promoted systematic confounder identification in indirect comparisons. By allocating variables to specific endpoints rather than treating confounding as a generic problem, the panel acknowledged a technical subtlety: a variable may be essential to adjust for when comparing progression-free survival but irrelevant for response rates, and a variable that predicts toxicity, such as tumor burden’s link to cytokine release syndrome, may need separate consideration in safety analyses.

There are caveats worth noting. The panel comprised six clinicians from two neighboring countries with broadly similar treatment landscapes, and their judgments, however experienced, are ultimately structured opinion rather than empirical proof. The study was funded by Miltenyi Biomedicine, a manufacturer of CAR-T technology, with several authors employed by the company or a contract research organization, although the funder reported no role in study design, data collection, or interpretation. Participants were compensated, and the elicitation captured physician judgment rather than patient-level data. These limitations do not undermine the central contribution, but they mean the resulting variable list should be treated as a validated starting framework, to be updated as real-world registries and comparative studies accumulate.

For patients with relapsed or refractory DLBCL, the practical stakes are considerable. CAR-T therapy has transformed outcomes for a population that once had few options, but the therapy is expensive, logistically demanding, and carries real risks, so payers and clinicians need trustworthy evidence about which product or sequence works best for whom. Indirect comparisons are often the only bridge across the gaps in randomized evidence, and this study supplies the engineering specifications for that bridge: a consensus-backed set of prognostic factors that must be balanced, a shorter and more tentative list of effect modifiers demanding caution, and an explicit mapping of variables to endpoints. The next step, the authors and the field suggest, is to test these expert-identified variables empirically in large, multinational real-world datasets, turning structured clinical intuition into statistically verified adjustment models that can withstand regulatory scrutiny.

Subject of Research: Confounder and effect-modifier identification for indirect treatment comparisons of CAR-T therapy in relapsed or refractory diffuse large B-cell lymphoma

Article Title: Confounder Identification in Diffuse Large B-Cell Lymphoma: Findings from an Expert Panel of German and Austrian Hematologists

Article References: Heger, J.-M., Gödel, P., Habringer, S., Jäger, U., Kutsch, N., von Tresckow, B., Zhang, R., Rungaldier, S., Oddsdottir, J., Zacharioudaki, M., & Mahlich, J. (2026). Confounder Identification in Diffuse Large B-Cell Lymphoma: Findings from an Expert Panel of German and Austrian Hematologists. Advances in Therapy. https://doi.org/10.1007/s12325-026-03820-z

Image Credits: AI Generated

DOI: 10.1007/s12325-026-03820-z

Keywords: diffuse large B-cell lymphoma, CAR-T therapy, confounders, prognostic factors, treatment-effect modifiers, indirect treatment comparisons, expert consensus, bridging therapy, cytokine release syndrome, International Prognostic Index, health technology assessment, hematology

The biological rationale for this call is straightforward once the mechanics of CAR-T therapy are understood. Before engineered T-cells are infused, patients typically receive lymphodepleting chemotherapy, a regimen designed to suppress their existing immune system so that the infused cells can expand without being rejected. This creates a window of profound immunosuppression, often compounded by severe neutropenia, in which the body’s defenses against bacteria, fungi, and viruses are dramatically weakened. At the same time, many candidates for CAR-T have already been through multiple lines of chemotherapy, which damages the oral mucosa, alters saliva production, and disrupts the delicate microbial ecosystem of the mouth. The result is that even a routine dental infection or an untreated cavity can become a serious systemic threat precisely when the patient is most vulnerable.

The oral cavity is, in fact, one of the most microbiologically dense environments in the human body, harboring hundreds of bacterial species alongside fungi such as Candida albicans. When mucosal barriers break down, as they commonly do during intensive cancer therapy, these microorganisms can translocate into the bloodstream. Recent research on Candida has shown how fungal cells can cross the intestinal epithelial barrier, and the same principle applies to oral tissues. In a patient recovering from lymphodepletion and facing the inflammatory storm of cytokine release syndrome, a dental abscess or fungal overgrowth is not a minor inconvenience; it is a potential source of sepsis, treatment delay, or even failure of the CAR-T product itself. Niscola and Del Principe emphasize that oral infectious complications are among the avoidable hazards that a structured dental evaluation could help prevent.

Evidence supporting this concern is accumulating. A retrospective observational study published in the same journal examined oral manifestations and dental management in patients undergoing CAR-T cell therapy and documented a range of problems, including mucositis, infections, and xerostomia, the distressing dryness of the mouth that follows damage to salivary glands. Related work in patients who have undergone allogeneic hematopoietic stem cell transplantation, a closely related form of cellular therapy, has measured long-term changes in the immunological components of saliva, suggesting that glandular function and mucosal immunity may take months or years to recover, if they recover at all. These findings paint a picture of the mouth as a barometer of systemic vulnerability, one that changes measurably during and after aggressive immunotherapy.

The functional consequences extend beyond infection. New clinical data on swallowing outcomes after CAR-T treatment in patients with non-Hodgkin lymphoma have documented dysphagia, or difficulty swallowing, as a real and underappreciated complication of the therapy pathway. Taste disturbances, or dysgeusia, have also been reported in association with immunotherapy, and recent translational work has explored microbiome-aware nutritional strategies to address them. When eating becomes painful, difficult, or unappetizing, patients lose weight, malnutrition sets in, and recovery slows. Oral health, in other words, is not a cosmetic concern but a determinant of whether a patient can maintain the nutritional and physical resilience needed to weather the acute phase of CAR-T therapy and benefit from it in the long run.

Recognizing these risks, the international supportive care community has begun to respond. In 2025, the Multinational Association of Supportive Care in Cancer and the International Society of Oral Oncology issued a joint clinical practice statement recommending dental evaluation and management before treatment for hematologic malignancies and before CAR-T cell therapy. The statement, authored by an expert panel including Zadik, Raber-Durlacher, Epstein, and colleagues, essentially formalizes what dental oncologists have long practiced: that patients scheduled for intensive immunotherapy should undergo a thorough oral examination, radiographic assessment, and stabilization of active disease before their immune system is deliberately dismantled. Niscola and Del Principe’s commentary can be read as both an endorsement of that guidance and a call to close the gap between recommendation and routine practice.

What would such integration look like in practice? The authors sketch a pathway that begins at patient selection, when a candidate for CAR-T is first identified. At that point, ideally weeks before lymphodepletion begins, a dentist or oral medicine specialist would assess caries risk, screen for periodontal disease and non-vital teeth, evaluate the condition of dentures and oral prostheses, and treat any source of potential infection. Preventive measures would include professional cleaning, fluoride application, and patient education on meticulous oral hygiene. During the hospital admission for infusion, the focus shifts to monitoring for mucositis, managing xerostomia with salivary substitutes or stimulants, and watching for early signs of oral candidiasis or herpes simplex reactivation. After discharge, follow-up dental visits would track healing, address persistent dry mouth or taste changes, and restore function as immune reconstitution proceeds.

The commentary also situates oral care within the broader architecture of CAR-T supportive management, which has grown increasingly sophisticated around toxicities such as cytokine release syndrome and immune effector cell-associated neurotoxicity. Guidelines for managing these systemic toxicities are now well established, and the authors suggest that oral supportive care deserves the same systematic attention. They point to their own prior work on mucosal toxicity in hematological malignancies, which reviewed prevention and management strategies across the spectrum of intensive therapies, as part of a growing literature arguing that the mucosal surfaces of the body are a frontline in cancer supportive care. The mouth, being simultaneously a sensory organ, a digestive gateway, and a microbial reservoir, sits at the intersection of several of these concerns.

There are practical challenges to implementing the vision. CAR-T therapy is delivered in a relatively small number of specialized centers, and patients often travel long distances for treatment, which complicates coordination with community dental providers. Many patients arrive with years of neglected dental care, particularly those whose cancer diagnosis interrupted routine checkups, and complete dental rehabilitation can take longer than the clinical window allows. Prioritization therefore becomes essential: treating active infection and removing unstable teeth take precedence over elective work, and the MASCC/ISOO statement offers a framework for triage. The authors argue that embedding a dental assessment checklist into the standard CAR-T workup, much as cardiac and infectious disease evaluations are already routine, would require modest resources but could prevent disproportionate harm.

Ultimately, the message of the commentary is one of integration rather than novelty. CAR-T cell therapy represents one of the most striking achievements of modern medicine, and its expanding applications across hematological malignancies continue to grow, as recent reviews of the field document. But the technology’s promise can only be realized if patients survive and thrive through the treatment window, and that depends on the unglamorous details of supportive care. Oral health, the authors contend, should no longer be an afterthought delegated to chance. By bringing dentists into the multidisciplinary team that plans and delivers CAR-T therapy, centers can reduce infectious complications, preserve nutrition and quality of life, and give patients the best possible chance of enjoying the remissions that this remarkable therapy can deliver.

Subject of Research: Integrating oral health and preventive dental care into CAR-T cell therapy supportive care

Article Title: Integrating oral health and preventive dental care into CAR-T cell therapy

Article References: Niscola, P., & Del Principe, M. I. (2026). Integrating oral health and preventive dental care into CAR-T cell therapy. Supportive Care in Cancer, 34(10), Article 1012. https://doi.org/10.1007/s00520-026-11268-8

Image Credits: AI Generated

DOI: 10.1007/s00520-026-11268-8

Keywords: CAR-T cell therapy, oral health, preventive dental care, supportive care, hematologic malignancies, mucositis, immunosuppression, dysgeusia, dysphagia, oral infections, immunotherapy, MASCC/ISOO guidelines

The research team, led by Adeena Musheer and colleagues working across institutions in Pakistan and the United States, conducted the review according to PRISMA 2020 guidelines, the current international standard for systematic evidence synthesis. They searched MEDLINE, Embase, the Cochrane Central Register of Controlled Trials, and grey literature sources from database inception through December 2025. To be included, studies had to report myeloid neoplasms diagnosed after CAR-T therapy or ASCT and provide extractable data on at least one of three parameters: incidence, latency, or molecular characteristics. Because the included studies varied enormously in design, patient populations, and reporting conventions, the authors synthesized their findings descriptively rather than attempting a meta-analysis, a decision that reflects an honest assessment of the state of the evidence. Nine studies comprising 2,933 patients ultimately met the inclusion criteria, and within those cohorts a total of 195 therapy-related myeloid neoplasm cases were reported.

One of the most striking findings concerns latency, the interval between the initial therapy and the diagnosis of the secondary cancer. The review found that median latency varied widely across studies, but the pattern differed meaningfully between the two treatment modalities. Following CAR-T therapy, reported median latency ranged from just 3 to 78 months, a window that in some cohorts was remarkably short. In contrast, ASCT cohorts reported longer intervals, spanning from 2.4 to as much as 262.8 months, meaning that some secondary leukemias appeared more than two decades after transplantation. This difference in timing is biologically intriguing. CAR-T therapy itself is not a classical DNA-damaging agent in the way that alkylating chemotherapy or total body irradiation are, so the shorter latency observed after CAR-T likely reflects the fact that these patients arrive at the therapy with bone marrows already heavily scarred by prior cytotoxic exposure, with pre-existing mutant clones poised for outgrowth once the selective pressures of treatment remove competing normal hematopoiesis.

That mechanistic picture is supported by the molecular data the review assembled. Half of the included studies assessed clonal haematopoiesis, the age-related phenomenon in which blood cells descended from a single mutated stem cell progressively dominate the marrow. Clonal haematopoiesis is increasingly understood as the soil in which therapy-related myeloid neoplasms grow: pre-leukemic clones carrying mutations in specific genes tolerate chemotherapy better than normal stem cells, expand to fill the void left by treatment, and in some patients acquire additional hits that drive full-blown malignancy. In the studies reviewed, the prevalence of clonal haematopoiesis ranged from 20 percent to over 80 percent, and crucially, higher rates were observed among patients who went on to develop therapy-related myeloid neoplasms. Recurrent mutations in three genes in particular, DNMT3A, TET2, and TP53, were consistently identified across both CAR-T and ASCT cohorts, underscoring that the two treatments share common biological underpinnings for this complication.

The identity of those three genes tells a coherent story. DNMT3A and TET2 are the two most commonly mutated genes in age-related clonal haematopoiesis in the general population, and both encode enzymes involved in DNA methylation regulation, a key epigenetic control mechanism in stem cells. Mutant TET2 and DNMT3A clones are known to be chemotherapy-resistant and to expand preferentially after cytotoxic treatment. TP53, by contrast, is the guardian of the genome, and mutations in it confer both resistance to certain therapies and a propensity toward genomic instability and aggressive leukemic transformation. The consistent finding of TP53 mutations in therapy-related myeloid neoplasms after both CAR-T and ASCT suggests that, in a subset of patients, the seeds of the secondary cancer are present before the transplant or CAR-T infusion even occurs, having been selected and amplified by earlier chemotherapy cycles.

The survival data in the review are sobering and represent perhaps its most clinically consequential message. Once a therapy-related myeloid neoplasm developed, outcomes were poor in both settings, but the prognosis was markedly worse after CAR-T therapy. Patients in CAR-T cohorts had a median overall survival of only 4.5 months following diagnosis of the secondary neoplasm, while ASCT cohorts fared better with a median overall survival of 18.4 months. Several factors could contribute to this disparity. Patients receiving CAR-T in the included studies may have had more heavily pretreated disease, more advanced clonal evolution by the time of the CAR-T infusion, or less reserve to tolerate intensive induction chemotherapy for the secondary leukemia. The authors themselves caution that these observations should be interpreted in the context of heterogeneous study designs and differing degrees of prior treatment exposure, so the comparison between modalities is not a head-to-head trial result but a signal that warrants prospective investigation.

The methodological limitations of the underlying evidence base are significant and the review does not shy away from them. Risk of bias was judged to be moderate to high across the included studies, primarily because of retrospective designs, confounding, and heterogeneity in how outcomes were reported. Retrospective cohort studies are vulnerable to incomplete follow-up, ascertainment bias in detecting secondary cancers, and the impossibility of fully adjusting for the many differences between patients who receive CAR-T versus those who proceed to ASCT. Because pooled incidence estimates could not be calculated, clinicians reading this review will not find a single number they can quote to a patient about their absolute risk. What they will find instead is a consistent qualitative picture: therapy-related myeloid neoplasms are a real and clinically significant complication in both settings, they occur with distinct latency patterns, and they are driven by shared clonal biology.

The implications for clinical practice are already taking shape. As CAR-T therapy expands from relapsed and refractory lymphomas and myelomas into earlier lines of treatment, the population of long-term survivors exposed to this modality is growing rapidly, and the review’s findings argue strongly for structured long-term surveillance of these patients. The authors highlight the need to incorporate molecular risk stratification strategies into the care of heavily pretreated patients. In practical terms, this could mean screening for clonal haematopoiesis before or after CAR-T infusion or transplant, with the presence of high-variant-allele-fraction TP53 or other high-risk mutations flagging patients who merit closer blood count monitoring and earlier referral for evaluation. Such an approach mirrors what is already being explored in solid tumor oncology, where clonal haematopoiesis testing is increasingly used to interpret circulating tumor DNA and to anticipate chemotherapy-associated complications.

For the field at large, this systematic review arrives at a pivotal moment. CAR-T cell therapy is one of the most celebrated advances in cancer medicine of the past decade, producing durable remissions in patients whose disease had exhausted every conventional option, and autologous transplantation remains a cornerstone of treatment for myeloma and lymphoma. The finding that 195 secondary myeloid cancers occurred among roughly 2,900 patients across nine studies does not diminish the value of these therapies, but it does define the frontier of the next challenge: preserving their remarkable benefits while identifying, before treatment, the minority of patients whose marrow clones place them at highest risk of a second malignancy. The review’s central contribution is to consolidate scattered single-center reports into a coherent evidence map, one that shows shorter latency and poorer survival after CAR-T, longer and more variable latency after ASCT, and a common molecular signature rooted in DNMT3A, TET2, and TP53. Converting that map into prospective screening programs, standardized reporting, and ultimately preventive strategies is the task the authors have set for the field, and it is one that will only grow more urgent as these therapies reach ever larger numbers of patients.

Subject of Research: Therapy-related myeloid neoplasms following CAR-T cell therapy and autologous stem cell transplantation

Article Title: Therapy-related myeloid neoplasms after CAR-T therapy and autologous stem cell transplantation: a systematic review of reported incidence, latency, and clonal haematopoiesis

Article References: Musheer, A., Mannan, M. S., Khan, M. W., Bhatti, A., Hafeez, A. S., Junaid, A., & Muhammad, S. (2026). Therapy-related myeloid neoplasms after CAR-T therapy and autologous stem cell transplantation: a systematic review of reported incidence, latency, and clonal haematopoiesis. Annals of Hematology. https://doi.org/10.1007/s00277-026-07305-5

Image Credits: AI Generated

DOI: 10.1007/s00277-026-07305-5

Keywords: therapy-related myeloid neoplasms, CAR-T therapy, autologous stem cell transplantation, clonal haematopoiesis, acute myeloid leukemia, myelodysplastic syndrome, DNMT3A, TET2, TP53, latency, systematic review, hematology

The starting point for this transformation is a sober clinical reality. Although most patients with marginal zone lymphoma experience favorable outcomes, approximately twenty percent relapse or progress early, within twenty-four months of initial treatment. That minority represents the central unsolved problem in the field. For these patients, the disease often reveals a more aggressive biology than its indolent label suggests, and the therapeutic options available after frontline therapy have historically been limited. It is precisely this population that the new generation of targeted and immune-based therapies aims to serve, and the review places their needs at the center of its analysis.

What has made precision medicine possible in this disease is the accumulation of detailed molecular profiling. The authors describe recurrent alterations in three major signaling axes: the B-cell receptor pathway, the NF-κB pathway, and NOTCH signaling. These are not random findings. Chronic antigen drive through the B-cell receptor, constitutive activation of NF-κB-dependent survival programs, and dysregulated NOTCH signaling together form the wiring diagram of the malignant marginal zone B cell. Layered on top of these are epigenetic changes that alter gene expression without changing the underlying DNA sequence, as well as abnormalities in the immune microenvironment that surrounds and supports the tumor. Each of these layers offers a potential point of therapeutic intervention, and each has spawned a corresponding class of drugs now in clinical evaluation.

Among the targeted agents, the strongest clinical evidence belongs to Bruton tyrosine kinase inhibitors, known as BTK inhibitors. BTK is a signaling molecule essential to B-cell receptor function, and blocking it effectively starves the malignant cell of one of its principal survival signals. In relapsed or refractory marginal zone lymphoma, these agents have produced durable responses and have become a cornerstone of second-line and later therapy. The review emphasizes, however, that their use is not without complications. First-generation BTK inhibitors carry risks of atrial arrhythmias, bleeding, and hypertension, and resistance can emerge through mutations in BTK itself or in downstream signaling components. Newer, more selective inhibitors aim to retain efficacy while narrowing the toxicity profile, and the choice of agent increasingly depends on patient comorbidities and treatment goals.

Beyond BTK inhibition, the review surveys two additional classes of small-molecule targeted therapy. BCL-2 inhibitors exploit a different vulnerability: the overexpression of an anti-apoptotic protein that allows lymphoma cells to evade programmed cell death. By releasing the mitochondrial brake on apoptosis, these agents can trigger tumor cell death directly, and they have been evaluated across B-cell malignancies with growing interest in marginal zone lymphoma. PI3K inhibitors, meanwhile, target a lipid kinase downstream of the B-cell receptor that promotes cell survival, proliferation, and trafficking. Their clinical history in indolent lymphomas has been complicated by immune-mediated toxicities, including colitis and pneumonitis, which has prompted closer regulatory scrutiny and a more careful approach to patient selection. The review stresses that efficacy must always be weighed against these safety considerations, particularly in an indolent disease where patients may live with treatment consequences for decades.

Monoclonal antibodies remain a foundational element of the therapeutic arsenal, and the review highlights how this class continues to evolve. Antibodies directed against CD20 have long formed the backbone of frontline treatment, and novel antibodies with enhanced immune-recruiting properties are extending this approach. Antibody-drug conjugates represent a further refinement, coupling the targeting specificity of an antibody to a potent cytotoxic payload that is released only after the drug reaches the tumor cell. This design concentrates chemotherapy’s killing power where it is needed while limiting collateral damage to healthy tissue. The result is a class of agents that blurs the traditional line between targeted therapy and cytotoxic treatment, offering a middle path with distinct pharmacological logic.

Perhaps the most striking advances described in the review lie in the realm of immune-based therapeutics. Bispecific antibodies are engineered molecules capable of binding two targets simultaneously: one arm attaches to a marker on the malignant B cell, while the other engages CD3 on T cells, physically bridging the two and forcing the immune system to attack the tumor. These off-the-shelf agents have demonstrated impressive activity in other indolent lymphomas and are being evaluated in marginal zone lymphoma across treatment settings. Chimeric antigen receptor T-cell therapy, or CAR-T, takes a different route to the same goal. A patient’s own T cells are harvested, genetically engineered to recognize a B-cell antigen such as CD19, expanded in the laboratory, and reinfused. The engineered cells then hunt down and destroy lymphoma cells throughout the body. For patients whose disease has failed multiple prior lines of therapy, these cellular and bispecific approaches have opened doors that simply did not exist a decade ago.

The review is careful to frame these advances within their limitations. Clinical evidence for several of the newer modalities in marginal zone lymphoma specifically remains less mature than in other B-cell malignancies, and the heterogeneity of the disease itself complicates interpretation. Marginal zone lymphoma encompasses distinct subtypes arising in different anatomical sites, from the stomach to the spleen to the lymph nodes, each with its own biology and treatment considerations. Extrapolating results from one subtype or from related lymphomas carries genuine uncertainty. The authors also emphasize the importance of biomarkers: molecular alterations identified at diagnosis or relapse may eventually guide which patients benefit from which agents, but validated predictive markers remain an aspiration rather than a routine clinical reality for many of these drugs.

Questions of treatment sequencing loom large over the entire field. With BTK inhibitors, BCL-2 inhibitors, PI3K inhibitors, antibody-based approaches, bispecifics, and CAR-T all now available or in development, clinicians face an increasingly complex decision tree. Should a novel targeted agent be deployed at first relapse, or should conventional therapy be exhausted first? Can immune-based approaches such as bispecific antibodies or CAR-T be moved earlier in the disease course, where patients may be fitter and more likely to tolerate them? How should resistance to one class of agent influence the choice of the next? The review addresses these questions directly, arguing that rational sequencing, informed by molecular profiling and by the toxicity profiles of successive therapies, will be essential to maximizing the benefit each approach can deliver over a patient’s lifetime.

What emerges from this comprehensive synthesis is a portrait of a disease in transition. Marginal zone lymphoma, once treated with a relatively blunt toolkit, is becoming a testing ground for the full breadth of modern cancer therapeutics, from kinase inhibitors that rewire intracellular signaling to engineered immune cells that patrol the body seeking malignant targets. The molecular alterations that drive the disease, in B-cell receptor, NF-κB, and NOTCH pathways, in the epigenome, and in the tumor microenvironment, are no longer merely descriptive findings; they are the blueprint for drug development. For the majority of patients who do well with current therapy, these advances promise more tailored and less toxic options when treatment is needed. For the twenty percent who relapse early, they represent something more consequential: a genuine expansion of hope, grounded in a deeper understanding of what keeps their cancer alive and how to take it apart.

Subject of Research: Targeted and immunotherapeutic strategies for marginal zone lymphoma

Article Title: Emerging frontiers in targeted and immunotherapeutic strategies for marginal zone lymphoma

Article References: Wang, X., Xiong, Q., Zhou, Y., Yu, M., & Li, F. (2026). Emerging frontiers in targeted and immunotherapeutic strategies for marginal zone lymphoma. Annals of Hematology. https://doi.org/10.1007/s00277-026-07288-3

Image Credits: AI Generated

DOI: 10.1007/s00277-026-07288-3

Keywords: marginal zone lymphoma, BTK inhibitors, BCL-2 inhibitors, PI3K inhibitors, bispecific antibodies, CAR-T therapy, immunotherapy, targeted therapy, NF-κB signaling, NOTCH signaling, B-cell lymphoma, antibody-drug conjugates